Protara Therapeutics Inc (TARA) — Cash Flow-to-Debt Ratio
Protara Therapeutics Inc (TARA) has a Cash Flow-to-Debt Ratio of -1.99x as of March 2026, meaning its operating cash flow of $-21.34 Million could theoretically repay -2% of its total liabilities ($10.71 Million) in one year. Explore TARA long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Protara Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Protara Therapeutics Inc across 14 annual periods. Also explore Protara Therapeutics Inc (TARA) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Protara Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Protara Therapeutics Inc. For market capitalisation and broader financial context, see TARA market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.32x | $-56.37 Million | $13.06 Million | ▼ -72.6% |
| 2024 | -2.50x | $-35.81 Million | $14.32 Million | ▲ +29.2% |
| 2023 | -3.53x | $-37.56 Million | $10.63 Million | ▼ -49.6% |
| 2022 | -2.36x | $-26.46 Million | $11.21 Million | ▲ +26.9% |
| 2021 | -3.23x | $-34.50 Million | $10.68 Million | ▲ +46.0% |
| 2020 | -5.98x | $-23.41 Million | $3.91 Million | ▲ +77.7% |
| 2019 | -26.84x | $-15.65 Million | $583.00K | ▼ -255.5% |
| 2018 | -7.55x | $-23.23 Million | $3.08 Million | ▼ -212.0% |
| 2017 | -2.42x | $-22.35 Million | $9.24 Million | ▲ +48.1% |
| 2016 | -4.66x | $-23.69 Million | $5.08 Million | ▼ -9.7% |
| 2015 | -4.25x | $-17.57 Million | $4.13 Million | ▲ +0.5% |
| 2014 | -4.27x | $-9.99 Million | $2.34 Million | ▼ -522.7% |
| 2013 | -0.69x | $-6.70 Million | $9.77 Million | ▲ +65.4% |
| 2012 | -1.98x | $-8.23 Million | $4.15 Million | — |